Michael K. Gibson, M.D., Ph.D.

Associate Professor

mike.gibson.1@vanderbilt.edu
Faculty Appointments
Associate Professor of Medicine
Education
Ph.D., Clinical Investigation, Johns Hopkins School of Medicine, Baltimore, MarylandM.D., Johns Hopkins School of Medicine, Baltimore, MarylandB.S., Biochemistry and Microbiology, North Carolina State University, Raleigh, North Carolina
Publications
Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J. Clin. Oncol [print-electronic]. 2017 May 5/10/2017; 35(14): 1542-9. PMID: 28328302, DOI: 10.1200/JCO.2016.70.1524, ISSN: 1527-7755.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck [print-electronic]. 2016 Dec; 38(12): 1759-64. PMID: 27232378, DOI: 10.1002/hed.24501, ISSN: 1097-0347.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann. Oncol [print-electronic]. 2016 Aug; 27(8): 1594-600. PMID: 27177865, PII: mdw204, DOI: 10.1093/annonc/mdw204, ISSN: 1569-8041.

Davison JM, Landau MS, Luketich JD, McGrath KM, Foxwell TJ, Landsittel DP, Gibson MK, Nason KS. A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes. Clin. Gastroenterol. Hepatol [print-electronic]. 2016 Mar; 14(3): 369-377.e3. PMID: 26515637, PMCID: PMC4776749, PII: S1542-3565(15)01486-X, DOI: 10.1016/j.cgh.2015.10.020, ISSN: 1542-7714.

Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS. The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am. J. Surg [print-electronic]. 2015 Oct; 210(4): 610-7. PMID: 26188709, PMCID: PMC4575853, PII: S0002-9610(15)00360-8, DOI: 10.1016/j.amjsurg.2015.05.010, ISSN: 1879-1883.

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri U, Kim S, Johnson JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys [print-electronic]. 2015 Mar 3/1/2015; 91(3): 480-8. PMID: 25680594, PII: S0360-3016(14)04404-6, DOI: 10.1016/j.ijrobp.2014.11.023, ISSN: 1879-355X.

Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J. Thorac. Cardiovasc. Surg [print-electronic]. 2015 Feb; 149(2): 538-47. PMID: 25454907, PMCID: PMC4492295, PII: S0022-5223(14)01549-9, DOI: 10.1016/j.jtcvs.2014.10.044, ISSN: 1097-685X.

Davison JM, Ellis ST, Foxwell TJ, Luketich JD, Gibson MK, Kuan SF, Nason KS. MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas. Hum. Pathol [print-electronic]. 2014 Mar; 45(3): 540-8. PMID: 24290360, PMCID: PMC3935247, PII: S0046-8177(13)00451-6, DOI: 10.1016/j.humpath.2013.10.020, ISSN: 1532-8392.

Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Räsänen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ, Farrant JM, Tosh D, Das KM, Bajpai M. Barrett's esophagus: cancer and molecular biology. Ann. N. Y. Acad. Sci. 2013 Oct; 1300: 296-314. PMID: 24117650, DOI: 10.1111/nyas.12252, ISSN: 1749-6632.

Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013 Sep; 108(4): 236-41. PMID: 23955427, PMCID: PMC3816713, DOI: 10.1002/jso.23392, ISSN: 1096-9098.

Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann. Surg. 2013 Jul; 258(1): 82-8. PMID: 23108119, DOI: 10.1097/SLA.0b013e318270500d, ISSN: 1528-1140.

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2/2/2013; 381(9864): 400-12. PMID: 23374478, PII: S0140-6736(12)60643-6, DOI: 10.1016/S0140-6736(12)60643-6, ISSN: 1474-547X.

Bali GS, Hartman DJ, Haight JB, Gibson MK. A rare case of malignant glomus tumor of the esophagus. Case Rep Oncol Med [print-electronic]. 2013; 2013: 287078. PMID: 24455358, PMCID: PMC3877612, DOI: 10.1155/2013/287078, ISSN: 2090-6706.

Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, Davison JM, R C, Irvin, Hoppo T, Nason KS, Kelly LA, Gibson MK, Jobe BA. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS ONE. 2013; 8(11): e78343. PMID: 24223792, PMCID: PMC3817247, PII: PONE-D-13-30734, DOI: 10.1371/journal.pone.0078343, ISSN: 1932-6203.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol [print-electronic]. 2013 Jan; 24(1): 220-5. PMID: 22898037, PMCID: PMC3525135, PII: mds245, DOI: 10.1093/annonc/mds245, ISSN: 1569-8041.

Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK. The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther. 2012 Apr; 12(4): 517-28. PMID: 22413826, DOI: 10.1517/14712598.2012.667397, ISSN: 1744-7682.

Defoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh. Am. J. Clin. Oncol. 2011 Dec; 34(6): 587-92. PMID: 22101387, PII: 00000421-201112000-00006, DOI: 10.1097/COC.0b013e3181f942af, ISSN: 1537-453X.

Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann. Oncol [print-electronic]. 2011 Nov; 22(11): 2482-8. PMID: 21363880, PMCID: PMC3200222, PII: mdr002, DOI: 10.1093/annonc/mdr002, ISSN: 1569-8041.

Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother. Pharmacol [print-electronic]. 2011 Oct; 68(4): 863-70. PMID: 21286719, PMCID: PMC3563156, DOI: 10.1007/s00280-011-1556-5, ISSN: 1432-0843.

Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, Oyama K, Miyashita T, Ohta T, Miwa K, Gibson MK, Zaidi A, Malhotra U, Atasoy A, Foxwell T, Jobe B. Barrett's esophagus and animal models. Ann. N. Y. Acad. Sci. 2011 Sep; 1232: 392-400. PMID: 21950831, PMCID: PMC4091915, DOI: 10.1111/j.1749-6632.2011.06061.x, ISSN: 1749-6632.

Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am. J. Clin. Oncol. 2011 Aug; 34(4): 372-9. PMID: 20859194, PMCID: PMC3177149, DOI: 10.1097/COC.0b013e3181e84dc0, ISSN: 1537-453X.

Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011 May 5/17/2011; 11: 176. PMID: 21586140, PMCID: PMC3118194, PII: 1471-2407-11-176, DOI: 10.1186/1471-2407-11-176, ISSN: 1471-2407.

Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am. J. Clin. Oncol. 2011 Apr; 34(2): 165-72. PMID: 20686406, DOI: 10.1097/COC.0b013e3181dbb73e, ISSN: 1537-453X.

Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J. Clin. Oncol [print-electronic]. 2010 Dec 12/20/2010; 28(36): 5294-300. PMID: 21079141, PMCID: PMC3018361, PII: JCO.2010.30.6423, DOI: 10.1200/JCO.2010.30.6423, ISSN: 1527-7755.

Gibson MK, Malhotra U. Targeted therapy: an evolving concept in esophageal adenocarcinoma. Oncology (Williston Park, N.Y.). 2010 Nov 11/15/2010; 24(12): 1143. PMID: 21141696, PII: 167188, ISSN: 0890-9091.

Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann. Oncol [print-electronic]. 2010 Nov; 21(11): 2278-83. PMID: 20430907, PII: mdq226, DOI: 10.1093/annonc/mdq226, ISSN: 1569-8041.

McLaughlin BT, Gokhale AS, Shuai Y, Diacopoulos J, Carrau R, Heron DE, Smith RP, Gibson MK, Ferris RL, Grandis JR, Johnson JT, Argiris A. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope. 2010 Jan; 120(1): 71-5. PMID: 19877245, DOI: 10.1002/lary.20697, ISSN: 1531-4995.

Gokhale AS, McLaughlin BT, Flickinger JC, Beriwal S, Heron DE, Ferris RL, Johnson J, Gibson MK, Argiris A, Smith RP. Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Ann. Oncol [print-electronic]. 2010 Jan; 21(1): 145-51. PMID: 19602566, PII: mdp268, DOI: 10.1093/annonc/mdp268, ISSN: 1569-8041.

Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann. Oncol [print-electronic]. 2009 Sep; 20(9): 1609-10. PMID: 19643807, PII: mdp382, DOI: 10.1093/annonc/mdp382, ISSN: 1569-8041.

Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ, Luketich JD. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann. Thorac. Surg. 2009 Apr; 87(4): 1048-54; discussion 1054. PMID: 19324126, PMCID: PMC2912110, PII: S0003-4975(08)02704-5, DOI: 10.1016/j.athoracsur.2008.12.060, ISSN: 1552-6259.

Walvekar RR, Li RJ, Gooding WE, Gibson MK, Heron D, Johnson JT, Ferris RL. Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. Laryngoscope. 2008 Dec; 118(12): 2129-34. PMID: 18948826, DOI: 10.1097/MLG.0b013e3181857950, ISSN: 1531-4995.

Miyashita T, Shah FA, Marti GP, Armstrong TD, Wang J, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan M, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. Dig. Dis. Sci [print-electronic]. 2008 Nov; 53(11): 2858-67. PMID: 18343998, DOI: 10.1007/s10620-008-0232-z, ISSN: 0163-2116.

Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann. Thorac. Surg. 2008 Jun; 85(6): 1930-6; discussion 1936. PMID: 18498797, PII: S0003-4975(08)00254-3, DOI: 10.1016/j.athoracsur.2008.01.097, ISSN: 1552-6259.

Daniels JA, Gibson MK, Xu L, Sun S, Canto MI, Heath E, Wang J, Brock M, Montgomery E. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am. J. Surg. Pathol. 2008 Mar; 32(3): 473-7. PMID: 18300801, DOI: 10.1097/PAS.0b013e3181582331, ISSN: 0147-5185.

Miyashita T, Shah FA, Marti G, Wang J, Armstrong T, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan MD, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. J. Gastrointest. Surg [print-electronic]. 2008 Jan; 12(1): 2-7; discussion 7. PMID: 17957441, DOI: 10.1007/s11605-007-0337-2, ISSN: 1091-255X.

Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol. 2007 May; 4(5): 282-94. PMID: 17464336, PII: ncponc0796, DOI: 10.1038/ncponc0796, ISSN: 1743-4262.

Yoon HH, Gibson MK. Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep. 2007 May; 9(3): 184-92. PMID: 17430689, ISSN: 1523-3790.

Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006 Jul; 7(7): 565-74. PMID: 16814208, PII: S1470-2045(06)70757-4, DOI: 10.1016/S1470-2045(06)70757-4, ISSN: 1470-2045.

Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4): 350-66. PMID: 16569388.

Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4): 328-47. PMID: 16569387.

Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, . Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2005 May 5/20/2005; 23(15): 3562-7. PMID: 15908667, PII: 23/15/3562, DOI: 10.1200/JCO.2005.01.057, ISSN: 0732-183X.

Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005 Feb; 10(2): 132-7. PMID: 15709215, PII: 10/2/132, DOI: 10.1634/theoncologist.10-2-132, ISSN: 1083-7159.

Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr Opin Oncol. 2004 May; 16(3): 220-4. PMID: 15069316, PII: 00001622-200405000-00005, ISSN: 1040-8746.

Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin. Cancer Res. 2003 Dec 12/15/2003; 9(17): 6461-8. PMID: 14695149, ISSN: 1078-0432.

Gibson MK, Forastiere AA. Combined-modality therapy for esophageal cancer: are we making progress?. Cancer J. 2003 Jul; 9(4): 238-40. PMID: 12967131, ISSN: 1528-9117.

Gibson MK, Villano SA, Huff CA, Cofrancesco J. Recrudescence of cutaneous Mycobacterium haemophilum lesions following tetanus immunization. Clin. Infect. Dis. 1999 Apr; 28(4): 919-20. PMID: 10825067, DOI: 10.1086/517245, ISSN: 1058-4838.

Buchhop S, Gibson MK, Wang XW, Wagner P, Stürzbecher HW, Harris CC. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res. 1997 Oct 10/1/1997; 25(19): 3868-74. PMID: 9380510, PMCID: PMC146972, PII: gka630, ISSN: 0305-1048.

Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher HW, Hoeijmakers JH, Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995 Dec 12/15/1995; 55(24): 6012-6. PMID: 8521383, ISSN: 0008-5472.

Gibson MK, Moore TA. Tropical Pyomyositis in a Patient From St. Croix. J Travel Med. 1995 Jun 6/1/1995; 2(2): 101-2. PMID: 9815371, ISSN: 1708-8305.

Migliaccio S, Davis VL, Gibson MK, Gray TK, Korach KS. Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology. 1992 May; 130(5): 2617-24. PMID: 1572285, DOI: 10.1210/endo.130.5.1572285, ISSN: 0013-7227.

Chae K, Gibson MK, Korach KS. Estrogen receptor stereochemistry: ligand binding orientation and influence on biological activity. Mol. Pharmacol. 1991 Nov; 40(5): 806-11. PMID: 1944245, ISSN: 0026-895X.

Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology. 1991 Oct; 129(4): 2000-10. PMID: 1915080, DOI: 10.1210/endo-129-4-2000, ISSN: 0013-7227.